Loading...
•
Dec 31, 2025
Castle Biosciences Q4 2025 Earnings Report
Castle Biosciences delivered modest fourth quarter 2025 revenue growth with strong core test volume expansion, while posting a small net loss.
Key Takeaways
Castle Biosciences reported Q4 2025 revenue of 87010000 with core revenue driver test report volume up 42% year-over-year. The quarter produced an operating loss of 3827000 and a net loss of 2332000, while non-dermatologic test revenue increased to 38400000.
Revenue was 87010000, up from 86311000 in Q4 2024.
Core revenue driver test reports (DecisionDx-Melanoma and TissueCypher) increased to 21825 from 15344 in Q4 2024.
Net loss was 2332000 versus net income of 9590000 in Q4 2024.
Non-dermatologic test revenue grew to 38400000 from 22500000 in Q4 2024.
Revenue by Segment
Forward Guidance
The company guided to 2026 total revenue of 340000000 to 350000000.
Positive Outlook
- Provided 2026 total revenue outlook of 340000000 to 350000000.
- Core revenue driver test reports grew 42% year-over-year in Q4.
- Non-dermatologic test revenue increased year-over-year in Q4.
- Gross margin percentage was 76.3% in Q4.
- Cash, cash equivalents and marketable investment securities totaled 299500000 at year-end.
Challenges Ahead
- Reported a Q4 net loss of 2332000.
- Operating loss was 3827000 in Q4.
- Adjusted gross margin percentage declined year-over-year in Q4.
- DecisionDx-SCC test report volume declined year-over-year in Q4.
- Revenue growth was 1% year-over-year in Q4.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...